Company intelligence / Profile preview

Tethys Bioscience

Emeryville, California, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~131
Development stage: Commercial

Overview

Tethys Bioscience developed and commercialized the PreDx Diabetes Risk Score, a fasting blood test combining multiple biomarkers and a proprietary algorithm to stratify patients' risk for developing type 2 diabetes. The company processed over 55,000 tests before closing. Its pipeline included additional diagnostic products for predicting risks of first-time heart attack, osteoporotic fracture, and other cardiometabolic diseases. The company ceased operations in 2014 when its assets were acquired by Human Diagnostics Labs.

Therapeutic areas: EndocrinologyCardiovascular
Modalities: Diagnostic test
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

PreDx Diabetes Risk Score

Commercial

Indications: Type 2 diabetes risk assessment

Beyond the preview

Go deeper on Tethys Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tethys Bioscience.

Explore the full profile